alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
EX-10.1(c)



 Exhibit 10.1(c) 
 June 1, 2011 
 AAA Capital Management Inc. 

1300 Post Oak Blvd. #350 
 Houston, Texas 77056

 Attention: Mr. Anthony Annunziato 
 Re: Management Agreement Renewals 
 Dear Mr. Annunziato: 

We are writing with respect to your management agreements concerning the commodity pools to which reference is made below (the “Management
Agreements”). We are extending the term of the Management Agreements through June 30, 2012 and all other provisions of the Management Agreements will remain unchanged. 

 

	 	•	 	 AAA Capital Energy Fund L.P. 


  

	 	•	 	 AAA Capital Energy Fund L.P. II 


  

	 	•	 	 AAA Master Fund LLC 


  

	 	•	 	 Orion Futures Fund L.P. 


  

	 	•	 	 Institutional Futures Portfolio L.P. 


  

	 	•	 	 Global Futures Fund LTD. 


  

	 	•	 	 Orion Futures Fund (Cayman) LTD. 


 Please acknowledge receipt of this modification by signing one copy of this letter and returning it to the attention of Ms. Jennifer Magro at the address above or fax to 212-296-6868. If you have any
questions I can be reached at 212-296-1302. 
 Very truly yours, 
 CERES MANAGED FUTURES LLC 
  

			
		
	By:	 	/s/ Jennifer Magro
		 	 Jennifer Magro
 Chief
Financial Officer & Director


  

			
	
	AAA CAPITAL MANAGEMENT INC.
		
	By:	 	/s/ Anthony Annunziato
	 Print Name:
	 	Anthony A. Annunziato
	 JM/sr
Exhibit 32.2 

CERTIFICATION 

        Theundersigned officer of DOV Pharmaceutical, Inc. (the “Company”) hereby certifiesthat the Company’s quarterly report on Form 10-Q to which this certification isattached (the “Report”), as filed with the Securities and Exchange Commission onthe date hereof, fully complies with the requirements of Section 13(a) or 15(d), asapplicable, of the Securities Exchange Act of 1934, as amended (the “ExchangeAct”), and that the information contained in the Report fairly presents, in allmaterial respects, the financial condition and results of operations of the Company. Thiscertification is provided solely pursuant to 18 U.S.C. Section 1350 and Item 601(b)(32) ofRegulation S-K (“Item 601(b)(32)”) promulgated under the Securities Act of 1933,as amended (the “Securities Act”), and the Exchange Act. In accordance withclause (ii) of Item 601(b)(32), this certification (A) shall not be deemed“filed” for purposes of Section 18 of the Exchange Act, or otherwise subject tothe liability of that section, and (B) shall not be deemed to be incorporated by referenceinto any filing under the Securities Act or the Exchange Act, except to the extent thatthe Company specifically incorporates it by reference. 

| Date: November 14, 2003 |   | By: | /s/  BARBARA G. DUNCAN      
Barbara G. Duncan    Vice President of Finance and    Chief Financial Officer
39 |
|-------------------------|--------|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------|
No. 11-5593.

#### Donald L. Stanfield, Petitioner v. F. Gonzales, Warden.

565 U.S. 946, 132 S. Ct. 404,

181 L. Ed. 2d 264,

2011 U.S. LEXIS 7429.

October 11, 2011.

Petition for writ of certiorari to the United States Court of Appeals for the Ninth Circuit denied.
HPV vaccination prevents 

cancer 

Human papillomavirus (HPV) infects about 13 million people, including teens, each year. While 

most HPV infections go away on their own, infections that don’t go away can lead to certain types of 

cancer. Every year, about 36,000 men and women develop a cancer caused by HPV. HPV vaccination 

could prevent more than 90% of these cancers from ever developing. The vaccine is made from one 

protein from the virus and is not infectious, meaning it cannot cause HPV infection or cancer. 

HPV vaccination is safe With more than 135 million doses distributed in the United States, HPV vaccine has a reassuring 

safety record that is backed by over 15 years of monitoring and research. As with all approved 

vaccines, CDC and FDA closely monitor the safety of HPV vaccines. 

Any detected safety concerns are reported to health officials, healthcare professionals, and the public. 

Data continue to show that HPV vaccination is safe and effective. 

HPV vaccination works The HPV vaccine works extremely well. Since HPV vaccination was introduced over in the U.S. in 2006, 

infections with HPV types that cause most HPV cancers and genital warts have dropped 88 percent 

among teen girls. Research has also shown that fewer women are developing cervical precancers 

(abnormal cells on the cervix that can lead to cancer). 

HPV vaccination provides 

long-lasting protection 

Studies show that the protection provided by HPV vaccine is long lasting. People who received 

HPV vaccination remained protected from the virus for more than 10 years, with no evidence of the 

protection decreasing over time. 

HPV vaccination can have Like any vaccine or medicine, HPV vaccination can have side e The most common side 

fainting, nausea, and headache. Fainting after any vaccine, including HPV vaccine, is more common 

among adolescents. To prevent fainting and injuries from fainting, anyone receiving HPV vaccine 

should be seated or lying down during vaccination and for 15 minutes after getting the shot. 

HPV vaccination doesn’t HPV vaccine does not cause fertility problems. However, not getting HPV vaccine leaves people 

vulnerable to HPV cancers and precancers. People who develop a cancer caused by HPV will need 

treatment that can sometimes limit their ability to have children, such as a hysterectomy, chemotherapy, 

or radiation. Treatment for cervical precancer could also put women at risk for problems with their cervix, 

which can sometimes cause preterm delivery. 

How can I get help paying for vaccines? 

The Vaccines for Children (VFC) program provides vaccines for children ages 18 years and younger, 

who are uninsured, Medicaid-eligible, American Indian or Alaska Native. Learn more at 

www.cdc.gov/vaccines/programs/vfc/parents/qa-detailed.html 

Last updated JULY 2021 

HPV Vaccine Safety and Effectiveness 

HPV vaccination provides safe, effective, and long-lasting protection against cancers caused by HPV. 

fleets. 

side effects effects are mild and include pain, redness, or swelling in the arm where the shot is given; dizziness, 

negatively affect fertility
No. 11-6800.

#### Paul Lee Driver, Petitioner v. Jen Landers, et al.

565 U.S. 1096, 132 S. Ct. 850,

181 L. Ed. 2d 555,

2011 U.S. LEXIS 8864.

December 12, 2011.

Petition for writ of certiorari to the United States Court of Appeals for the Ninth Circuit denied.

Same case below, 444 Fed. Appx. 934.
벼룩 매개 티푸스 | 알아야 될 점

벼룩 매개 티푸스는 감염된

벼룩 또는 그들의 배설물

(벼룩 먼지라고도 부름)

에서 발견되는 세균에 의해

야기됩니다.

벼룩 또는 벼룩 먼지와

접촉하더라도 모를 수

있습니다.

애완동물은 집 안 그리고 집

주변에 벼룩을 가지고 올 수

있습니다.

쓰레기나 음식 찌꺼기로 쥐 및

기타 유해 동물이 집에 모여들

수 있습니다.

벼룩은 집 근처의 유기 또는 야생

동물(고양이, 쥐 또는 주머니쥐 같은)

에서 볼 수 있습니다

벼룩과의 접촉을

피하십시오.

애완동물에 벼룩 치료를

하십시오.

야외에서는 EPA에 등록된

방충제를 사용하십시오.

집에서 설치류를 멀리 하십시오.

구멍들을 막으십시오!

쥐 및 생쥐를 덫으로 잡으십시오!

쓰레기를 치우십시오!

벼룩 또는 유기나 야생

동물과 접촉한 후 열, 

신체 통증, 오심, 구토

또는 발진이 있을 경우

의료 서비스 제공자와

상담하십시오.

열 근육통 오심, 구토 또는 위통 발진 벼룩 매개 티푸스는

치료 가능하므로 즉시

의료 서비스 제공자와

상담하십시오!

자세한 정보는 다음으로 연락하십시오.

CS310079A MLS311766 - Korean www.cdc.gov/typhus/murine/
Exhibit 32.2





CERTIFICATION
PURSUANT TO


18 U.S.C.
SECTION 1350,


AS
ADOPTED PURSUANT TO


SECTION
906 OF THE SARBANES-OXLEY ACT OF 2002





In
connection with the quarterly report of Infosmart Group, Inc. (the “Company”) on
Form 10-Q for the period ending March 31, 2010 as filed with the Securities and
Exchange Commission (the “Report”), I, Fan Chun Wang, Chief Financial Officer
(Principal Financial Officer) of the Company, hereby certify as of the date
hereof, solely for purposes of Title 18, Chapter 63, Section 1350 of the
United States Code, that to the best of my knowledge:





(1) The
Report fully complies with the requirements of Section 13(a) or 15(d), as
applicable, of the Securities Exchange Act of 1934, as amended, and





(2) The
information contained in the Report fairly presents, in all material respects,
the financial condition and results of operations of the Company at the dates
and for the periods indicated.




Date:
      May 14, 2010
            
            /s/
      Fan Chun WangFan
      Chun WangChief
      Financial Officer
              (Principal
      Financial Officer)





A signed
original of this written statement required by Section 906 has been
provided to the Company and will be retained by the Company and furnished to the
Securities and Exchange Commission or its staff upon request.
No. 11-6460.

#### Rosie Washington, et vir, Petitioners v. Louisiana, et al.

565 U.S. 1056, 132 S. Ct. 797,

181 L. Ed. 2d 478,

2011 U.S. LEXIS 8536.

November 28, 2011.

Motion of petitioners for leave to proceed in forma pauperis *479denied. Petitioners are allowed until December 19, 2011, within which to pay the docketing fee required by Rule 38(a) and to submit a petition in compliance with Rule 33.1 of the Rules of this Court.

Same case below, 425 Fed. Appx. 330.
(1) Adjusting Price $17.38 CWT

(2) Base Price $18.09 CWT

(3) Change from Base Price per CWT ($0.71)

(4) Price change per gallon ($0.0610)

(Line (3) divide by 11.63 gallons/cwt)

(5) Price change per half gallon ($0.0305)

Price change per quart ($0.0153)

Price change per pint ($0.0076)

Price change per 12-oz pg. ($0.0057)

Price change per 1/3 qt. (10-oz) ($0.0048)

Price change per half pint ($0.0038)

(6) Price adjustment per gallon ($0.06)

Price adjustment per half gallon ($0.03)

Price adjustment per quart ($0.02)

Price adjustment per pint ($0.01)

Price change per 12-oz pg. ($0.01)

Price adjustment per 1/3 qt. (10-oz) ($0.00)

Price adjustment per half pint ($0.00)

NOTE: Numbers in brackets are negative or decreases, all others are positive or increases.

Monthly EPA Calculation for Class I Milk (Clause 52.216-9032 Alt. I)

Based on California Dept. of Food and Agriculture Announcement of Minimum Prices

 Effective Date: Oct. 4, 2015
No. 11-198.

#### Juan Tomas Rojas Nieto, Petitioner v. Eric H. Holder, Jr., Attorney General.

565 U.S. 944, 132 S. Ct. 420,

181 L. Ed. 2d 260,

2011 U.S. LEXIS 7357.

October 11, 2011.

Petition for writ of certiorari to the United States Court of Appeals for the Fifth Circuit denied.

Same case below, 425 Fed. Appx. 385.
Letter from the General Partner extending Management Agreement



 Exhibit 10.6(a) 
 June 1, 2011 
 Altis Partners (Jersey) Limited 

2 Hill Street 
 St Helier, Jersey 

Channel Islands JE2 4UA 
 Attention: Mr. Stephen
Hedgecock 
 Re: Management Agreement Renewals 
 Dear Mr. Hedgecock: 
 We are writing with respect to your management agreements concerning the
commodity pools to which reference is made below (the “Management Agreements”). We are extending the term of the Management Agreements through June 30, 2012 and all other provisions of the Management Agreements will remain unchanged.

  

	 	•	 	 CTA Capital LLC 


  

	 	•	 	 Global Diversified Futures Fund L.P. 


  

	 	•	 	 Emerging CTA Portfolio L.P. 


  

	 	•	 	 CMF Altis Partners Master Fund L.P. 


  

	 	•	 	 Institutional Futures Portfolio L.P. 


  

	 	•	 	 Global Futures Fund Ltd. 



Please acknowledge receipt of this modification by signing one copy of this letter and returning it to the attention of Ms. Jennifer Magro at the address
above or fax to 212-296-6868. If you have any questions I can be reached at 212-296-1302. 
 Very truly yours, 

CERES MANAGED FUTURES LLC 
  

			
	By:	 	 /s/ Jennifer Magro

		 	Jennifer Magro
		 	Chief Financial Officer and Director

 ALTIS PARTNERS (JERSEY) LIMITED 
  

			
	By:	 	 /s/ Stephen Hedgecock

		 	Print Name: Stephen Hedgecock

 JM/sr
APP B

DSCPH 4155.2

************************

ITEM: Bacon, Canadian Style, * MONOGRAPH NO.: 1D3

 Cured, Smoked, Sliced ************************

 In Brine (BCS) PRIMARY

NSN: 8905-01-151-2488 ITEM SPECIFICATION: MIL-B-44232

APPROXIMATE CALORIC VALUE PER SERVING: 139

CHARACTERISTICS OF ITEM:

 APPEARANCE: Moist surface with dark casing and possibly a thin bend of fat. Color profile: Light 

to medium pinkish tan, with tan to reddish-brown casing.

 ODOR: Briny with a slight cured pork (ham) aroma.

 FLAVOR: Typical of cured ham; salty with a slight smoky flavor.

 

 TEXTURE: Tender, friable.

 ESTIMATED SHELF-LIFE AT 70 DEGREES F: 36 months

 80 DEGREES F: 24 months

90 DEGREES F: 18 months

 100 DEGREES F: 12 months

EXPECTED DETERIORATIVE CHANGES: 

 

 APPEARANCE: Product may become darker. Brine may become slightly cloudy. Slices may 

become unshingled and tend to break up.

 

 ODOR: Product may become stale.

 FLAVOR: Slightly stale. Product may become saltier tasting.

 TEXTURE: Product may become dry and stringy.

UNIQUE EXAMINATION/TEST PROCEDURES: None.

SPECIAL NOTES : Can is designed to yield 18 servings of approximately 3 slices each (93 grams).
Exhibit 32.1



Certification Pursuant to

18 U.S.C.  Section 1350,

as Adopted Pursuant to

Section 906 of the Sarbanes-Oxley Act
2002



In connection with
the Annual Report on Form 40-F of Sierra Metals Inc. (the “Company”) for the yearly period ended December 31, 2017,
as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Igor Gonzalez, President
and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to Section 906 of the
Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:



| | (1) | The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange
Act of 1934; and
| | --- | ---------------------------------------------------------------------------------------------------------------------



| | (2) | The information contained in the Report fairly presents, in all material respects, the financial
condition and results of operations of the Company.
| | --- | ----------------------------------------------------------------------------------------------------------------------------------------------------



|/s/ Igor Gonzalez |                                      
|----------------- | -------------------------------------
|Name:             | Igor Gonzalez                        
|Title:            | President and Chief Executive Officer
|Date:             | March 22, 2018                       



The foregoing certificate
is solely for the purposes of compliance with the aforementioned Section 906 of the Sarbanes-Oxley Act 2002 and is not intended
to be used or relied upon for any other purposes.



A signed original of
this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished
to the SEC or its staff upon request.
**
**Exhibit 32.2**

**CERTIFICATION PURSUANT TO**

**18 U.S.C. SECTION 1350,**

**AS ADOPTED PURSUANT TO**

**SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

In connection with the Annual Report of Starwood Real Estate Income Trust, Inc. (the “Company”) on Form10-K for the period ended December 31, 2017 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Chris Lowthert, Chief Financial Officer of theCompany, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that: 

 
 1.The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and 
 
 2.The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. 
 
/s/ Chris LowthertChris LowthertChief Financial Officer and Treasurer
March 30, 2018 

Thiscertification accompanies each Report pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by the Sarbanes- Oxley Act of 2002, be deemed filed by the Company for purposes of Section 18 ofthe Securities Exchange Act of 1934, as amended. 

A signed original of this written statement required by Section 906 has been provided by theCompany and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request. 
**
<PAGE>

                                                                    EXHIBIT 32.1

                    CERTIFICATION OF CHIEF EXECUTIVE OFFICER
            PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002


The undersigned, the Chief Executive Officer of Metallurg Holdings, Inc. (the
"Company"), hereby certifies on the date hereof, pursuant to 18 U.S.C. 1350(a),
as adopted pursuant to Section 906 of The Sarbanes-Oxley Act of 2002, that the
Quarterly Report on Form 10-Q for the quarter ended September 30, 2003 ("Form
10-Q"), filed concurrently herewith by the Company, fully complies with the
requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934,
as amended, and that the information contained in the Form 10-Q fairly presents,
in all material respects, the financial condition and results of operations of
the Company.


Date: November 10, 2003

                                           /s/ Heinz C. Schimmelbusch
                                        -------------------------------
                                        Heinz C. Schimmelbusch
                                        Chief Executive Officer
Pero sabía que sus pre-adolescentes 

y adolescentes necesitan vacunas?

días como este.

Usted sabía que habría

Los niños mayores, preadolescentes y adolescentes 

necesitan vacunas también incluyendo las vacunas 

Tdap, meningocócica, HPV y la de la influenza.

Pregúntele al doctor o enfermera de su hijo 

si necesita vacunas para protegerlo contra 

enfermedades graves.

http://www.cdc.gov/spanish/inmunizacion

Departamento de 

Salud y Servicios Humanos

Centros para el Control y la 

Prevención de Enfermedades

CS223139-E
EXHIBIT 31.1


CERTIFICATION PURSUANT TO 18 U.S.C. ss.1350 AS ADOPTED
PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

      In connection with the Quarterly Report on Form 10-QSB of Power
Technology, Inc. (the "Company") for the quarter ended April 30, 2005, as filed
with the Securities and Exchange Commission on the date hereof (the "Report"),
the undersigned President, Treasurer and Chief Financial Officer of the Company
each hereby certify, pursuant to 18 U.S.C. ss.1350, as adopted pursuant to
Section 906 of the Sarbanes-Oxley Act of 2002, that:

      1. The Report fully complies with the requirements of Section 13(a) or
15(d) of the Securities Exchange Act of 1934; and

      2. The information contained in the Report fairly presents, in all
material respects the financial condition and results of operations of the
Company.

Dated: September 14, 2005

                                               /s/ Bernard J. Walter
                                               ---------------------
                                               Bernard J. Walter, President,
                                               Treasurer and
                                               Chief Financial Officer
**EXHIBIT
      32.2**





**CERTIFICATION
      PURSUANT TO**


**18
      U.S.C. SECTION 1350**


**AS
      ADOPTED PURSUANT TO**


**SECTION
      906 OF THE SARBANES-OXLEY ACT OF 2002**





In
      connection with the Quarterly Report of theglobe.com, inc. (the "Company")
      on
      Form 10-Q for the period ending September 30, 2006, as filed with the Securities
      and Exchange Commission on the date hereof (the "Report"), I, Edward A.
      Cespedes, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C.
      Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act
      of
      2002, that to the best of my knowledge and belief:





(1)
      The
      Report fully complies with the requirements of Section 13(a) or 15(d) of the
      Securities Exchange Act of 1934; and





(2)
      The
      information contained in the Report fairly presents, in all material respects,
      the financial condition and results of operations of the Company.


*Date:
                November 10, 2006*
            By:
            /s/*Edward
                A. Cespedes**Edward
                A. Cespedes*
              *Chief
                Financial Officer*
No. 11-7367.

#### Leo Slaughter, Petitioner v. United States.

565 U.S. 1129, 132 S. Ct. 1043,

181 L. Ed. 2d 767,

2012 U.S. LEXIS 25.

January 9, 2012.

Petition for writ of certiorari to the United States Court of Appeals for the Eighth Circuit denied.
5 June 2020 ************************* 

NSN: 8925-01-591-4123 (PCDS) MONOGRAPH NO. M8O5

 ************************* 

Item: Pan coated candy, Disks, Fruit flavored, Sour (Type IV, Style A, Flavor 2, Flavor Style d)

Document: CID A-A-20177F, Candy and Chocolate Confections and PKG & QAP

Approximate Caloric Value Per Serving: 250 Component Classification: Primary

Estimated Shelf Life: 36 months at 80°F

Item Characteristics

Appearance:

The pan coated candy shall have a candy shell with a high gloss and the colors shall be 

vibrant (high chroma) and uniform (not mottled) in hue. Disks shall resemble a double 

convex lens in shape. The candy shall consist of five various fruit colors. The candy 

shall have an evenly distributed coating of fine sugar.

Odor: Mild to moderately sweet, sour and fruit odor of the five following odors: orange, 

strawberry, green apple, lemon, and grape.

Flavor: Mild to moderately sweet, sour and fruit flavor of the five following fruit flavors: 

orange, strawberry, green apple, lemon, and grape.

Texture: Hard exterior candy shell with a firm chewy center.

Possible Deteriorative Changes 

Appearance: Cracked candy shell, mottling and dulling of color, interior darkening.

Odor: Off odors, heat stressed.

Flavor: Burnt, caramelized sugars.

Texture: Moderate hardening of center, brittle center, hardening to the point of causing 

discomfort to the user.

Unique Examination/Test Procedures

NA

Special Notes

NA
No. 11-6400.

#### Kevin L. Fuqua, Petitioner v. Claude E. Finn, Warden.

565 U.S. 1040, 132 S. Ct. 586,

181 L. Ed. 2d 431,

2011 U.S. LEXIS 8267.

November 14, 2011.

Petition for writ of certiorari to the United States Court of Appeals for the Ninth Circuit denied.
Analytical Report for Premanufacture Notice 

Study Title: 

Product Name: -

CAS Nr:

Lot Nr:

Color Index: -------- 

Request Number: 

Requestor: 

 

Test Facility: 

 

 
 

e

 

TABLE OF CONTENTS 

1. ABSTRACT .................................................................................................................................................................. 2

2 STRUCTURES OF MAIN COMPONENT AND BY PRODUCTS ........................................................................ 3

3 ARCHIVATION AND DISTRIBUTION .................................................................................................................. 3

3.1 ARCHIVE ..................................................................................................................................................................... 3

3.2 DISTRIBUTION .......................................................................................................................................................... 3

4 RESULTS ...................................................................................................................................................................... 4

4.1 NMR SPECTROSCOPY .................................................................................. 4

4.2 FTIR-ATR SPECTROSCOPY ( .............................................................................................................. 9

4.3 ELEMENTAL ANALYSIS ....................................................................................................................................... 12

4.4 CONTENT OF MAIN PRODUCT AND BY PRODUCTS BY HPLC ) ............................................. 13

1. Abstract 

 

 

 

 
 

 

 

. 
 

 

 

 

 

 

 

 
 

 

 

 

 

 
 

 

 

 

 
 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 -1 

 
 
νsohOag
 

h 

1